カテゴリ： Allied Market Research, 世界, 医療/バイオ

幹細胞治療のグローバル市場（2021〜2031）：脂肪組織由来間葉系幹細胞、骨髄由来間葉系幹細胞、臍帯血/胚性幹細胞、その他

■ 英語タイトル：Stem cell therapy Market By Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells, Other), By Application (Cancer, Musculoskeletal Disorder, Wounds and Injuries, Cardiovascular Disease, Other), By Type (Allogeneic Transplants, Autologous Transplants): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23JN109）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23JN109
■ 発行日：2034年9月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：274
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[幹細胞治療のグローバル市場（2021〜2031）：脂肪組織由来間葉系幹細胞、骨髄由来間葉系幹細胞、臍帯血/胚性幹細胞、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本調査資料では、2021年に205.12百万ドルであった世界の幹細胞治療市場規模が、2031年までに928.6百万ドルに到達し、2022年から2031年の間に年平均16.2%で拡大すると予測しています。本資料は、幹細胞治療の世界市場について総合的に調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、細胞由来別（脂肪組織由来間葉系幹細胞、骨髄由来間葉系幹細胞、臍帯血/胚性幹細胞、その他）分析、用途別（がん、筋骨格障害、傷・怪我、心血管疾患、その他）分析、種類別（同種移植、自家移植）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などの項目を以下の構成でまとめております。本資料は、Allele Biotechnology and Pharmaceuticals, Inc.、Astellas Pharma Inc.、Fujifilm Holding Corporation、Mesoblast Ltd.、Novadip Biosciences、NuVasive, Inc.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の幹細胞治療市場規模：細胞由来別
-脂肪組織由来間葉系幹細胞における市場規模
-骨髄由来間葉系幹細胞における市場規模
-臍帯血/胚性幹細胞における市場規模
-その他における市場規模
・世界の幹細胞治療市場規模：用途別
-がんにおける市場規模
-筋骨格障害における市場規模
-傷・怪我における市場規模
-心血管疾患における市場規模
-その他における市場規模
・世界の幹細胞治療市場規模：種類別
-同種移植における市場規模
-自家移植における市場規模
・世界の幹細胞治療市場規模：地域別
- 北米の幹細胞治療市場規模
- ヨーロッパの幹細胞治療市場規模
- アジア太平洋の幹細胞治療市場規模
- 中南米・中東・アフリカの幹細胞治療市場規模
・企業状況
・企業情報

世界の幹細胞治療市場は、2021年には2億512万ドルと評価され、2022年から2031年までの年平均成長率は16.2%を記録し、2031年には9億2,864万ドルに達すると予測されています。

幹細胞治療は、幹細胞の移植によって損傷した臓器や組織、機能を再生させる有望な戦略です。細胞治療では、治癒を目的として細胞を体内に直接投与します。このアプローチにおける治療の単位は単一細胞です。血液悪性腫瘍や一部の固形癌に対する有用な治療法として確立されています。しかし、同種幹細胞移植ではTリンパ球が致命的なGVHDを引き起こすため、患者の一部は依然として死亡しており、自家幹細胞移植では幹細胞移植後に病気が再発するため、多くは治癒しません。一方、非造血幹細胞の研究と使用は、がん治療の毒性を最小限に抑えたり、非悪性疾患を治療するのに役立ちます。

幹細胞治療に対する需要の増加、研究開発活動に対する政府支援の増加、医療支出の増加により、世界の幹細胞治療市場は予測期間中に大きく成長すると予想されます。さらに、がんなどの疾患の増加や、幹細胞治療に関連する新製品の上市も、市場成長に大きく寄与しています。しかし、倫理的な問題から胚性幹細胞の使用が制限されていることや、幹細胞治療のコストが高いことが、市場成長にマイナスの影響を与えています。逆に、胚性幹細胞治療における人工多能性幹細胞の応用の急増は、市場成長に有利な機会を提供しています。

世界の幹細胞治療市場は、細胞源、用途、種類、地域によって区分されます。細胞源別では、市場は脂肪組織由来間葉系幹細胞、骨髄由来間葉系幹細胞、臍帯血/胚性幹細胞、その他に分類されます。用途別では、がん、筋骨格系疾患、創傷・外傷、心血管疾患、消化器疾患、その他に分類されます。種類別では、同種移植と自家移植に分類されます。さらに、同種移植と自家移植は、それぞれ小児と成人に細分化されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、欧州のその他地域）、アジア太平洋（中国、日本、オーストラリア、インド、韓国、アジア太平洋のその他地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、LAMEAのその他地域）に市場を分けて分析しています。

本レポートに掲載されている主要企業には、Allele Biotechnology and Pharmaceuticals, Inc.、Astellas Pharma Inc.、富士フィルムホールディングス株式会社 (フジフイルム・セルラー・ダイナミクス)、Mesoblast Ltd.、Novadip Biosciences、NuVasive, Inc.、Orthofix Holdings, Inc.、Smith & Nephew plc、武田薬品工業、U.S. Stem Cell, Inc.などがあります。

ステークホルダーにとっての主なメリット
・本レポートは、2021年から2031年までの幹細胞治療市場分析の市場セグメント、現在のトレンド、予測、ダイナミクスを定量的に分析し、幹細胞治療市場の有力な機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース（5つの力）分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・幹細胞治療市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国について、世界市場における収益貢献度をマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解するのに役立ちます。
・幹細胞治療の地域別、世界の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を収録

〈主要市場セグメント〉
細胞源別
脂肪組織由来間葉系幹細胞
骨髄由来間葉系幹細胞
臍帯血／胚性幹細胞
その他

用途別
がん
筋骨格系障害
創傷・外傷
循環器疾患
その他

種類別
同種移植
自家移植

地域別
・北米
米国
カナダ
・ヨーロッパ
ドイツ
フランス
イギリス
その他のヨーロッパ
・アジア太平洋
日本
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
その他のLAMEA地域

〈主要市場プレイヤー〉
Allele Biotechnology and Pharmaceuticals, Inc.
アステラス製薬株式会社
富士フイルムホールディング株式会社
Mesoblast Ltd.
Novadip Biosciences
NuVasive, Inc.
Orthofix Holdings, Inc.
Smith & Nephew plc
武田薬品工業株式会社
U.S. Stem Cell, Inc.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: STEM CELL THERAPY MARKET, BY CELL SOURCE
4.1 Overview
4.1.1 Market size and forecast
4.2 Adipose Tissue-Derived Mesenchymal Stem Cells
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Bone Marrow-Derived Mesenchymal Stem Cells
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Cord Blood/Embryonic Stem Cells
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Other
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: STEM CELL THERAPY MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Cancer
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Musculoskeletal Disorder
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Wounds and Injuries
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Cardiovascular Disease
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Other
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
CHAPTER 6: STEM CELL THERAPY MARKET, BY TYPE
6.1 Overview
6.1.1 Market size and forecast
6.2 Allogeneic Transplants
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Allogeneic Transplants Stem cell therapy Market by Age
6.2.4.1 Pediatric Market size and forecast, by region
6.2.4.2 Adult Market size and forecast, by region
6.3 Autologous Transplants
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 Autologous Transplants Stem cell therapy Market by Age
6.3.4.1 Pediatric Market size and forecast, by region
6.3.4.2 Adult Market size and forecast, by region
CHAPTER 7: STEM CELL THERAPY MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Cell Source
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by Type
7.2.4.1 North America Allogeneic Transplants Stem cell therapy Market by Age
7.2.4.2 North America Autologous Transplants Stem cell therapy Market by Age
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Cell Source
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by Type
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Cell Source
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by Type
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Cell Source
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by Type
7.3.4.1 Europe Allogeneic Transplants Stem cell therapy Market by Age
7.3.4.2 Europe Autologous Transplants Stem cell therapy Market by Age
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Cell Source
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by Type
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Cell Source
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by Type
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Cell Source
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by Type
7.3.5.4 Rest of Europe
7.3.5.4.1 Market size and forecast, by Cell Source
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by Type
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Cell Source
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by Type
7.4.4.1 Asia-Pacific Allogeneic Transplants Stem cell therapy Market by Age
7.4.4.2 Asia-Pacific Autologous Transplants Stem cell therapy Market by Age
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Cell Source
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by Type
7.4.5.2 India
7.4.5.2.1 Market size and forecast, by Cell Source
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by Type
7.4.5.3 South Korea
7.4.5.3.1 Market size and forecast, by Cell Source
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by Type
7.4.5.4 Rest of Asia-Pacific
7.4.5.4.1 Market size and forecast, by Cell Source
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by Type
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Cell Source
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by Type
7.5.4.1 LAMEA Allogeneic Transplants Stem cell therapy Market by Age
7.5.4.2 LAMEA Autologous Transplants Stem cell therapy Market by Age
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Cell Source
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by Type
7.5.5.2 Rest of LAMEA
7.5.5.2.1 Market size and forecast, by Cell Source
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by Type
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Allele Biotechnology and Pharmaceuticals, Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Astellas Pharma Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Fujifilm Holding Corporation
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Mesoblast Ltd.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novadip Biosciences
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 NuVasive, Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Orthofix Holdings, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Smith & Nephew plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Takeda Pharmaceutical Company Ltd
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 U.S. Stem Cell, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 2. STEM CELL THERAPY MARKET, FOR ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. STEM CELL THERAPY MARKET, FOR BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. STEM CELL THERAPY MARKET, FOR CORD BLOOD/EMBRYONIC STEM CELLS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. STEM CELL THERAPY MARKET FOR CORD BLOOD/EMBRYONIC STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. STEM CELL THERAPY MARKET, FOR OTHER, BY REGION, 2021-2031 ($MILLION)
TABLE 9. STEM CELL THERAPY MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. GLOBAL STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 11. STEM CELL THERAPY MARKET, FOR CANCER, BY REGION, 2021-2031 ($MILLION)
TABLE 12. STEM CELL THERAPY MARKET FOR CANCER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. STEM CELL THERAPY MARKET, FOR MUSCULOSKELETAL DISORDER, BY REGION, 2021-2031 ($MILLION)
TABLE 14. STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. STEM CELL THERAPY MARKET, FOR WOUNDS AND INJURIES, BY REGION, 2021-2031 ($MILLION)
TABLE 16. STEM CELL THERAPY MARKET FOR WOUNDS AND INJURIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. STEM CELL THERAPY MARKET, FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 18. STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. STEM CELL THERAPY MARKET, FOR OTHER, BY REGION, 2021-2031 ($MILLION)
TABLE 20. STEM CELL THERAPY MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 22. STEM CELL THERAPY MARKET, FOR ALLOGENEIC TRANSPLANTS, BY REGION, 2021-2031 ($MILLION)
TABLE 23. STEM CELL THERAPY MARKET FOR ALLOGENEIC TRANSPLANTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. GLOBAL ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 25. STEM CELL THERAPY MARKET, FOR PEDIATRIC, BY REGION, 2021-2031 ($MILLION)
TABLE 26. STEM CELL THERAPY MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
TABLE 27. STEM CELL THERAPY MARKET, FOR AUTOLOGOUS TRANSPLANTS, BY REGION, 2021-2031 ($MILLION)
TABLE 28. STEM CELL THERAPY MARKET FOR AUTOLOGOUS TRANSPLANTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. GLOBAL AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 30. STEM CELL THERAPY MARKET, FOR PEDIATRIC, BY REGION, 2021-2031 ($MILLION)
TABLE 31. STEM CELL THERAPY MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
TABLE 32. STEM CELL THERAPY MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 35. NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 36. NORTH AMERICA ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 37. NORTH AMERICA AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 38. NORTH AMERICA STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 39. U.S. STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 40. U.S. STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 41. U.S. STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 42. CANADA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 43. CANADA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 44. CANADA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 45. EUROPE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 46. EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 47. EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 49. EUROPE AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 50. EUROPE STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 51. GERMANY STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 52. GERMANY STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 53. GERMANY STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. FRANCE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 55. FRANCE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 56. FRANCE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. UK STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 58. UK STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 59. UK STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 69. JAPAN STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 70. JAPAN STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 71. JAPAN STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 72. INDIA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 73. INDIA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 74. INDIA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 75. SOUTH KOREA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 76. SOUTH KOREA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 77. SOUTH KOREA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 80. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 81. LAMEA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 82. LAMEA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 83. LAMEA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 84. LAMEA ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 85. LAMEA AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 86. LAMEA STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 87. BRAZIL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 88. BRAZIL STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 89. BRAZIL STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. REST OF LAMEA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 91. REST OF LAMEA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 92. REST OF LAMEA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 93.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 94.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 95.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 96.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: NET SALES,
TABLE 97.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 98.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 99.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
TABLE 100.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
TABLE 101.ASTELLAS PHARMA INC.: NET SALES,
TABLE 102.ASTELLAS PHARMA INC.: KEY STRATERGIES
TABLE 103.FUJIFILM HOLDING CORPORATION: COMPANY SNAPSHOT
TABLE 104.FUJIFILM HOLDING CORPORATION: OPERATING SEGMENTS
TABLE 105.FUJIFILM HOLDING CORPORATION: PRODUCT PORTFOLIO
TABLE 106.FUJIFILM HOLDING CORPORATION: NET SALES,
TABLE 107.FUJIFILM HOLDING CORPORATION: KEY STRATERGIES
TABLE 108.MESOBLAST LTD.: COMPANY SNAPSHOT
TABLE 109.MESOBLAST LTD.: OPERATING SEGMENTS
TABLE 110.MESOBLAST LTD.: PRODUCT PORTFOLIO
TABLE 111.MESOBLAST LTD.: NET SALES,
TABLE 112.MESOBLAST LTD.: KEY STRATERGIES
TABLE 113.NOVADIP BIOSCIENCES: COMPANY SNAPSHOT
TABLE 114.NOVADIP BIOSCIENCES: OPERATING SEGMENTS
TABLE 115.NOVADIP BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 116.NOVADIP BIOSCIENCES: NET SALES,
TABLE 117.NOVADIP BIOSCIENCES: KEY STRATERGIES
TABLE 118.NUVASIVE, INC.: COMPANY SNAPSHOT
TABLE 119.NUVASIVE, INC.: OPERATING SEGMENTS
TABLE 120.NUVASIVE, INC.: PRODUCT PORTFOLIO
TABLE 121.NUVASIVE, INC.: NET SALES,
TABLE 122.NUVASIVE, INC.: KEY STRATERGIES
TABLE 123.ORTHOFIX HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 124.ORTHOFIX HOLDINGS, INC.: OPERATING SEGMENTS
TABLE 125.ORTHOFIX HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 126.ORTHOFIX HOLDINGS, INC.: NET SALES,
TABLE 127.ORTHOFIX HOLDINGS, INC.: KEY STRATERGIES
TABLE 128.SMITH & NEPHEW PLC: COMPANY SNAPSHOT
TABLE 129.SMITH & NEPHEW PLC: OPERATING SEGMENTS
TABLE 130.SMITH & NEPHEW PLC: PRODUCT PORTFOLIO
TABLE 131.SMITH & NEPHEW PLC: NET SALES,
TABLE 132.SMITH & NEPHEW PLC: KEY STRATERGIES
TABLE 133.TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT
TABLE 134.TAKEDA PHARMACEUTICAL COMPANY LTD: OPERATING SEGMENTS
TABLE 135.TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO
TABLE 136.TAKEDA PHARMACEUTICAL COMPANY LTD: NET SALES,
TABLE 137.TAKEDA PHARMACEUTICAL COMPANY LTD: KEY STRATERGIES
TABLE 138.U.S. STEM CELL, INC.: COMPANY SNAPSHOT
TABLE 139.U.S. STEM CELL, INC.: OPERATING SEGMENTS
TABLE 140.U.S. STEM CELL, INC.: PRODUCT PORTFOLIO
TABLE 141.U.S. STEM CELL, INC.: NET SALES,
TABLE 142.U.S. STEM CELL, INC.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 皮膚がん治療のグローバル市場（2021〜2031）：黒色腫、非黒色腫
  • 自家細胞治療のグローバル市場（2021〜2031）：がん、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23JN109 )"幹細胞治療のグローバル市場（2021〜2031）：脂肪組織由来間葉系幹細胞、骨髄由来間葉系幹細胞、臍帯血/胚性幹細胞、その他" (英文：Stem cell therapy Market By Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells, Other), By Application (Cancer, Musculoskeletal Disorder, Wounds and Injuries, Cardiovascular Disease, Other), By Type (Allogeneic Transplants, Autologous Transplants): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。